nosed with NF1 as a teenager, and had no family history of NF1, implicating a new germline mutation.
Examination. Physical examination revealed grade 4 weakness of the left abductor pollicis brevis and opponens pollicis muscles and 4+ weakness of flexor digitorum sublimis, with normal power in muscles innervated by the ulnar and radial nerves. Pinprick sensation was decreased in the left ring finger. No masses were noted on palpation of her supra-and infraclavicular brachial plexus. Magnetic resonance (MR) imaging of the cervical spine revealed multiple extradural spinal tumors, the largest involving the C-2 nerve roots. Electromyography and nerve conduction studies demonstrated diminished motor and sensory amplitudes of the median nerve, with absence of sensory nerve action potentials upon sensory stimulation of the left ring finger. The clinical diagnosis was that of a neurofibroma involving the proximal median nerve, which was not clinically palpable. Empirical therapy with amitriptyline was initiated, which provided good control of her sensory symptoms.
One year following her initial presentation, she developed a large, tender, nonpulsatile mass in her left arm, just medial to the biceps muscles, which developed rapidly over 3 to 4 days. Her neurological examination was unchanged from her original examination, and the vascular examination was normal. Magnetic resonance imaging demonstrated a mass anterior to the neurovascular bundle in the left arm with no evidence of gross intratumoral hemorrhage (Fig. 1 left) . Magnetic resonance angiography excluded a peripheral vascular etiology from her acute presentation.
First Operation. Infraclavicular brachial plexus exploration revealed a 12-cm fusiform, vascularized mass, arising from the median nerve (Fig. 1 right) . The tumor was very edematous, with a necrotic center, but gross intratumoral hemorrhage was not encountered. Intraoperative nerve stimulation proximal to the lesion yielded little motor activity in the hand, with the majority of median nerve fibers being carried by the ulnar nerve (Martin-Gruber anastomosis). 24 Gross resection of the median nerve tumor (from the junction of the medial and lateral cord contributions of the median nerve to the biceps tendon) was performed and did not precipitate any added postoperative neurological deficit. No attempt was made during this initial operation to obtain tumor-free margins, pending confirmation of the diagnosis of neurogenic sarcoma. She was discharged for further oncological workup, which did not demonstrate any metastatic disease.
Second Operation. Subsequently, the decision to reoperate was made with the goal of obtaining tumor-free margins on the nerve and resecting the adjacent muscle and fascial compartment. This was to be followed by a course of local radiotherapy to obtain local disease control. However, prior to scheduled readmission, 2 months following her initial surgery, the patient noted a rapid increase in the size of the operative site over a period of less than 1 week. Reexploration of the operative site on an urgent basis revealed sarcomatous cells invading the adjacent muscles and proximal and distal median nerve ends. The tumor mass itself was once again extremely necrotic, and local tumor-free margins could not be obtained despite sacrificing the axillary artery. Histologically, the tumor showed similar aggressive features to those found in the initial resection.
Postoperative Course. Postoperative MR imaging revealed residual local disease, with no evidence of pulmonary metastases. A forequarter amputation was undertaken to obtain local disease control. Despite tumor-free margins at the time of amputation, the patient has developed evidence of pulmonary metastases 3 months following her amputation and is now undergoing chemotherapy.
Pathological Examination
The surgical specimen consisted of a 12-cm ϫ 5-cm fusiform mass, with an area of central cavitation representing approximately one-half of the tumor. The gross appearance was of a myxoid firm tissue with areas of yellowish discoloration and smaller regions of focal hemorrhage. Histological examination confirmed the origin of the tumor from a plexiform neurofibroma, corresponding to the thickened nerve trunks seen at the periphery of the tumor. The tumor itself consisted of malignant spindle cells arranged predominantly in intersecting streams and fascicles ( Fig. 2 upper left) , which were arising from and merging with the plexiform neurofibroma. The nuclei were wavy, with occasional perinuclear cytoplasmic vacuoles. There were no areas of heterologous elements such as cartilage, bone, or skeletal muscle differentiation. There was extensive tumor necrosis ( Fig. 2 lower right) and small scattered regions of recent hemorrhage were present. Mitotic activity was brisk (Fig. 2 upper left) , with an average of one mitosis per high-power field. Invasion into adjacent fascia and skeletal muscle was present, with infiltration of intratumoral vascular lamina in several regions ( Fig. 2 lower left) . Immunohistochemical studies with antisera to glial fibrillary acid protein, S-100 protein, epithelial membrane antigen, keratin, and desmin were all negative, but there was strong positivity to vimentin. The monoclonal antibody MIB-1, directed against the Ki-67 antigen, 4,26 is a marker of cellular proliferation; it was positive in greater than 5% of this patient's nuclei (Fig. 2 upper right), in keeping with the high cellularity and mitotic rate. Negative immunohistochemical findings for p53 in this patient using mouse anti-human monoclonal p53 antibody, clone DO-7, (Dako Corp., Carpinteria, CA) suggest the absence of p53 mutations, as such mutations produce conformational changes in the protein, resulting in an increased half-life. 21, 31 Mutational analysis, however, would be required to make a definitive statement regarding the p53 gene in this neurogenic sarcoma.
Molecular Examination
Total RNA was isolated from flash-frozen surgical specimens, including the neurogenic sarcoma from the first operation, to determine NF1 expression by reverse transcription-polymerase chain reaction (RT-PCR; Fig. 3  upper left) , as previously detailed.
14,17 Cyclophilin expres-
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Acute presentation of a neurogenic sarcoma sion was used to control for RNA loading and comparison made to a schwannoma from a patient without NF1. The neurogenic sarcoma had a marked decrease in NF1 messenger RNA expression compared to the schwannoma. Western blot (Fig. 3 lower left) and immunohistochemical analyses (Fig. 3 upper and lower right) with an antibody against human neurofibromin were performed on the specimen. Embryonic mouse fibroblasts, with homozygous knockout of both NF1 alleles (NF1:Ϫ/Ϫ) and those from normal mice (NF1:+/+) were used as negative and positive controls, respectively, in the Western blot analysis. Both Western blot and immunohistochemical analyses demonstrated absence of neurofibromin in the neurogenic sarcoma cells from our patient, compared to abundant expression in a schwannoma from a patient without NF1.
Neurogenic sarcoma cell lines derived from patients with NF1, which demonstrate absence of neurofibromin, have also been found to express high levels of activated Ras-GTP. Similar quantification, however, has not previously been shown in actual tumor tissues, due to a lack of a tissue-based assay. In collaboration with other researchers, we have developed an assay applicable to tissues.
14 Three separate determinations from different regions of the neurogenic sarcoma derived from our patient were assayed for levels of activated Ras-GTP. In comparison to a group of schwannomas from patients without NF1, levels of activated Ras-GTP were increased 15 times in the neurogenic sarcoma specimens.
14

Discussion
Neurofibromatosis type 1 has a birth incidence of 1: 2500 to 3000, and a prevalence of 1:4000 to 5000. 25 It is a hereditary disorder, being transmitted in an autosomal dominant fashion with high penetrance. As in our patient, 30% to 50% of cases are due to de novo mutations. 8, 32 The hallmark of NF1 is the neurofibroma, with 40% to 42% of neurofibromas occurring in patients with NF1. 29, 34 The risk of malignant transformation in non-NF1 neurofibromas is less than 1%, 2,12 whereas the risk is substantially higher in NF1 patients; neurogenic sarcomas occur in 3% to 4.6% of NF1 patients. 11, 33, 35 Neurogenic sarcomas, also commonly known as neurofibrosarcomas, are referred to as malignant peripheral nerve sheath tumors in the new World Health Organization classification of soft-tissue sarcomas. 42 The typical presentation of a neurogenic sarcoma consists of pain, an enlarging mass, and a neurological deficit; these symptoms usually develop over months to years. 11 Pathological evaluation of these tumors commonly reveals single-cell or geographic regions of necrosis; large regions of gross necrosis, as seen in our patient, however, are uncommon. 18, 41 Traditionally, poorer prognosis in neurogenic sarcomas has been linked to larger tumor size, the presence of heterologous elements, and occurrence in the setting of NF1. Pathological findings of necrosis, high cellularity, and microvascular proliferation, however, do not appear to alter survival rates in neurogenic sarcomas significantly. 41 This is not the case with nonneurogenic soft-tissue sarcomas, in which the presence of vascular invasion and tumor necrosis are a more common finding and can be useful clinically in prognosticating a poorer outcome. 15, 16 More recently, the presence of molecular markers such as mutations in the p53 gene and in the p53 regulator mdm2, and strong Ki-67 staining on immunohistochemistry, have been shown to correlate with poorer prognosis in soft-tissue sarcomas. 6, 10 Our patient demonstrated more diffuse tumor necrosis than is typically seen in neurogenic sarcomas; this is explained pathologically by ischemic infarction resulting from rapid cellular proliferation outstripping the tumor's vascular supply. Ischemia was likely augmented by the direct vascular invasion by tumor cells seen in this patient. The presence of these aggressive pathological features in our patient correlated with an aggressive clinical course and development of pulmonary metastases within 7 months of presentation.
The NF1 gene was isolated and cloned in 1990, after being localized to the pericentromeric region of the long arm of chromosome 17 (17q11.2). 43 Its gene product, known as neurofibromin, helps regulate cellular growth and differentiation by modulating activity in intracellular signal transduction pathways. In particular, neurofibromin regulates the Ras pathway, converting activated Ras-GTP to inactive Ras-guanosine diphosphate (Fig. 4) . 1, 19, 20, 27, 43 Absence of neurofibromin would result in increased levels of activated Ras-GTP, causing uncontrolled mitogenic signals to be sent to the nucleus, resulting in increased cellular proliferation. All patients with NF1 possess a germline mutation (that is, in all body cells) of one NF1 gene copy. Mutation or loss of the second allele results in absence of neurofibromin in those cells possessing the second (somatic) mutation. This would predispose to tumor formation. As we have shown in this paper, the neurogenic sarcoma from our NF1 patient demonstrated a markedly decreased expression of neurofibromin, both at the messenger RNA and protein levels (Fig. 3) ; this was associated with increased levels of Ras-GTP. 14 Because loss of both NF1 alleles and loss of neurofibromin expression is responsible for tumor formation, it has been postulated that such mutations predispose to formation of benign neurofibromas. Such neurofibromas similarly lack expression of neurofibromin, as in our neurogenic sarcoma.
14 It is likely that subsequent mutations in non-NF1 genes are responsible for sarcomatous transformation of benign neuurofibromas; candidate genes include p53, mdm2 and the retinoblastoma gene RB1. 3, 6, 23, 28 Ras itself is synthesized as a nonfunctional cytosolic precursor, which is dependent on posttranslational modification by protein farnesyltransferase (PFTase) for its sub- sequent activation and biological effects. 7, 13, 22 A number of pharmacological PFTase inhibitors are currently under development. 13, 22 Because absence of neurofibromin in NF1 results in increased levels of activated Ras-GTP, inhibition of Ras synthesis, using such PFTase inhibitors, may be therapeutically useful in the tumors seen in NF1 patients.
